Quantafuel (QFUEL) today announced that mechanical recycling at Kristianslund started operations. It is the first cash generating business for Quantafuel that is in operation.
The target annual capacity of the mechanical recycling line is 20 000 tonnes per year. The start up will be gradual – current capacity of 10k will be increased to 20k by the end of 2Q22.
Kristianslund EBITDA higher than guided?
Originally QFUEL announced they expect annual ERBITDA of 25 million NOK from the mechanical recycling at Kristianslund. Today press release stated:
“Although we still have limited production volumes, a number of shipments have been made at market prices significantly higher than budgeted.“
This could indicate, that there might be an upside in the 25 million EBITDA guidance.
Chemical recycling at Kristiansundnext
Chemical recycling plant construction in Kristiansund should start next year and should take 24 months to complete
SKIVE
No update on Skive provided today
During the Pareto presentation the management announced that the cold commissioning of Skive modifications should start early December. This means the cold commissioning should start any day now.
The next step is to reach a proof of concept. The management guided, that this should be achieved around the year end. That is few weeks from now.
Proof of concept – it is a self-imposed hurdle by QFUEL mgmt. They originally imposed three hurdles:
(i) run one line at the full capacity,
(ii) run two lines in parallel, and
(iii) run one line for a defined number of days and generate product at required specifications.
The first two hurdles were already achieved, the third is guided to be reached around the year-end.
After QFUEL achieves the Proof of Concept on one line, they will aim to reach continuous production. They are guiding that should be achieved in 1Q22.
All four lines are guided to be running at continuous production in 2Q22
Quantafuel is presenting today at Bank of America conference
This is quite positive – for two reasons
QFUEL broadens investor universe in the US, and
QFUEL presentation could result in BoA trading in QFUEL shares for its clients – that could result in research coverage by BoA.
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.
Biovica reported its Quarterly results today. Below is Pareto Summary of the report:
Biovica today released its Q2 21/22 report highlighting some progress with clinical studies and pharmaceutical companies while the FDA remains silent. Biovica is still waiting for feedback from the FDA as of end of November and does not expect anymore to get approval for DiviTum before year end. Meanwhile, net sales (research related) have increased to SEK 268k (44) while the operating loss has increased to SEK -14m (-8). Despite the regulatory delays, the value proposition is as clear as ever and thus we reiterate our Buy rating on BIOVIC with a target price of SEK 103.
New clinical data expected in December Biovica keeps building its clinical data library with more results expected to be presented at the San Antonio Breast Cancer Symposium (SABCS), which will take place during 7-10 December. – Positive results from the clinical study PROMISE (NCT03281902) performed at Mayo clinic – Positive results from a clinical study performed with Carrick Therapeutics – According to the company, the data will further confirm DiviTum’s prognostic value in CDK4/6 inhibitor treated metastatic breast cancer patients (this is a second potential use to DiviTum’s treatment monitoring capabilities)
Increasing demand from pharmaceutical companies The company noted an increasing demand from pharmaceutical companies such as most recently Carrick Therapeutics that is developing a CDK7 inhibitor (samuraciclib). Carrick had reached out to Biovica to investigate whether DiviTum could complement their drug development. First results were presented at SABCS 2021 in triple negative breast cancer, where DiviTum was able to monitor samuraciclib treatment and thus has shown to be a useful monitoring tool also for future CDK inhibitors.
Current status
Biovica is waiting for a feedback from the FDA on last open issues. After that will submit updated application, which should result in FDA approval. For the value of the stock, it is not relevant, if that happens two weeks or two months later. FDA Covid-caused FDA congestion should not impact the value. FDA related 50% sell off is an opportunity. The relevant issue are:
The likelihood of the FDA approval is very high – Pareto gives this 95% probability.
After the FDA approval the share price should re-rate strongly
There will be further material catalysts right after approval – mainly theimminent start of the US sales and agreement on reimbursement with US insurers (expected within two months of the approval)
In 2022 Biovica will file application for other cancer tests
I spoke to the analysts, they believe that next year Biovica could become a takeover target.
Redeye has a bullish scenario over 300 SEK. It is not unrealistic, that we could see this share price value next year
I believe Biovica offers very attractive risk/reward in Scandinavian Healthcare. The share price should at least double after FDA approval and potentially multiply further next year. If you doubled your money playing Xbrane with me, this ride might be even better.
Biovica is reporting on 1/12/2021. The link to webcast is below:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.
So far the world has experienced 260 million covid cases with 5 million deaths – I calculated implied death rate is 2%
Last week we had 3.8 million new cases with 48k death – I calculated implied death rater of 1.2%
Cases and deaths in Europe doubled in last two months
99% of cases is Delta now
Europe has still low vaccination coverage in some countries even in most exposed population segments
Even whole population immunization will not fully interrupt transmissions – continued transmission is likely with new variants
Omicron has large number of mutations
It is not certain yet whether Omicron is more transferable vs other Covid variants (slide 13)
It is also not certain yet whether Omicron causes more or less severe disease compared to other Covid variants (slide 13)
Impact on vaccines is not yet known. The current base case is that the vaccination should protect against severe Omicron disease (this is my WHO friend explanation of the wording on slide 14).
There will be more variants. We need to prepare for more Covid waves.
We should know much more about Omicron within 2-3 weeks (again this is information from my WHO friend, not in the presentation)
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.
I have been long Biovica (BIOVIC) for some time. The thesis has been delayed by the FDA approval delay due to FDA Covid congestion. Many retail investors lost patience. The stock is down, but the thesis is unchanged. One or two months delay should not affect the value of the company. FDA Covid-caused FDA congestion should not impact the value. FDA related 50% sell off is an opportunity. We have been buyers.
Current status
Biovica is waiting for a feedback from the FDA on last open issues. That could come any day now. After that they will submit updated application, which should result in FDA approval. The base case is that this should still happen this year. For the value of the stock, it is not relevant, if that happens two weeks or two months later. The relevant issue are:
The likelihood of the FDA approval is very high – Pareto gives this 95% probability.
After the FDA approval the share price should re-rate strongly
There will be further material catalysts right after approval – mainly theimminent start of the US sales and agreement on reimbursement with US insurers (expected within two months of the approval)
In 2022 Biovica will file application for other cancer tests
I spoke to the analysts, they believe that next year Biovica could become a takeover target.
Redeye has a bullish scenario over 300 SEK. It is not unrealistic, that we could see this share price value next year
I believe Biovica offers very attractive risk/reward in Scandinavian Healthcare. The share price should at least double after FDA approval and potentially multiply further next year. If you doubled your money playing Xbrane with me, this ride might be even better.
Biovica is reporting on 1/12/2021. The link to webcast is below:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
HAV Group(HAV) reported another strong quarterly results. I enclose below a summary from Fearnley report today. I also include a brief summary of Kyoto Group capital market day. Finally, I enclose Pareto take on Bioinvent short term opportunity. Pareto analyst is very bullish Bioinvent, so we are.
Top ideas from Fearnley Energy conference 24/11/21:
In the introduction, Fearnley analysts presented a few top ideas – interesting investment cases that presented in the conference. The below were mentioned:
Scatec Solar – analysts likes Scatec diversification into hydro. Buy with PT 195
Kyoto Group – thermal energy batteries producer, that last week announced its first sales. Buy with PT 90
Acer Carbon Capture – sell recommendation due to recent high price appreciation – it now trades at 4 times 2025 sales.
Technip Energies – trading at cheap multiples. PT 21 EURO. Trades at 9xP/E. Similar companies trade at 15x P/E. It is a doubling candidate.
All in all, a solid report from HAV this morning, with continued strong cash flow and hiked margin guidance. HAV reported 3q21 revenues of NOK 81m, which is down from NOK 304m last quarter and well below our NOK 147m estimate with the drop largely due to less trading. EBITDA was NOK 14.5m, in-line with FSest. NOK 14m. Else, we note continued strong cash flows with YTD FCF of NOK 229m (incl. NOK 162m in WC movements), which increased HAV’s cash position to NOK 406m from NOK 334m last quarter. Notably, HAV has managed to increase its cash position by NOK >370m YTD. External backlog now totals NOK 542m, which is up from NOK 468m last quarter providing strong visibility going forward. The increase follows strong orders in NES and NGT, partly offset by a drop in HAV Design.
On the outlook, HAV sees continued strong fundamentals for maritime cleantech. Further, HAV maintains the NOK 850-950m revenue target, which is in-line with FSest. NOK 905m. However, with a YTD EBIT of NOK 67m, HAV expects the full-year EBIT margin to be in-line with YTD 3q21, meaning roughly 10% vs. previous guiding at c. 7%. As such, we expect to see strong numbers coming out of 4q21. Note, at the midpoint, this implies NOK 207m in revenues for 4q21 and NOK 20m in EBIT to bring full-year EBIT in-line with YTD margins. This compares to FSest. NOK 12m in EBIT for 4q21, and we thus see some 11% upside on our FY’21 EBIT estimate.
Further, we highlight the announcement that HYARD (owns c. 66% of the shares in HAV) announced to distribute an extraordinary dividend of up to 50% of its holding in HAV (subject to EGM on Dec-14th). Distributed is expected to shareholders on Dec-27th. I.e., HYARD is going to offer up to 33% of the total shares in the company, meaning that HYARD’s ownership in HAV will max. go down to c. 33% from the current 66.46%. Whilst we expect some downwards sales pressure on HAV, very positive longer-term in terms of increasing liquidity (free float will increase by up to 33%). Notably, HAV announced this morning a 3.5m share-buyback programme representing c. 10% of shares outstanding in the company
Kyoto held their capital markets day yesterday at Salt in Oslo with an update on the market and on operational progress. Importantly, the company secured their first contract with Aalborg Forsyning this week for the installation of the first battery at Nordjyllandsværket (NJV). NJV is one three coal fired power plants in Denmark providing around 1.4 TWh of heat and power annually. The plant has committed to phasing out coal by 2028. In terms of near-term growth, KYOTO highlights the metal- and energy industry as prospects in Europe. Further, the initial target markets are Norway, Denmark, UK, Germany and Spain.
The company has set an ambitious target towards 2025 reaching several hundred batteries installed, CAPEX < 40 EUR/kWh and being a billion NOK revenue company. In terms of key developments on the way, we note a doubling of the organization next year, explore M&A opportunities and financing and develop the next generation of the Heatcube.
Pareto Securities update on Bioinvent
BINV – BioInvent, Buy TP SEK 115: We continue to see a unique and short-lived discount to BioInvent’s share price due to two bigger upcoming triggers in December (possibly 11-13th and latest on 17th). In December we will get additional data from BINV’s lead drug BI-1206 in two programs. BI-1206 showed strong data in NHL in January and a bit more this November, which makes as confident that the higher dose cohorts to be reported in December will be (at least as) positive too. Further, based on insights from a Novartis-Beigene drug Tislelizumab, an anti-PD-1 checkpoint inhibitor with Fcγ interaction-minimizing properties, we are confident that BI-1206+Pembrolizumab (Keytruda) will have an effect in the much bigger area of solid tumors (data to be reported on December 17th). We re-iterate our Buy rating with a TP of SEK 115.
Bioinvent invited investors to their Key Opinion Leader Webinar on BI-1206. Registration link below:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
When Kjetil Bohn left Quantafuel,he stated he wants to focus on his other investments. One of them is Kyoto Group (KYOTO), where Kjetil is one of the largest shareholders. Yesterday KYOTO announced its first commercial contract for its thermal battery.
KYOTO market cap is 191m NOK. The company reported cash position from 1H21 of 157m NOK. It means that 80% of the market capitalization is covered by cash.
Fearnley issued an analyst report on the event. Its price target for Kyoto is 90 NOK, the current share price is around 25NOK. Plenty of upside.
I enclose below Summary from the Fearnley Securities Report on KYOTO
Contract Signed for First Heatcube Thermal Battery What’s new: Signs contract with one of three coal fired power plants in Denmark Our take: Positive to see the project moving according to schedule and a customer with potential strong appetite for additional Heatcube’s
KYOTO announced on Friday after close the signing of its first commercial contract for its Heatcube thermal battery solution. The battery is expected operational from early 2022 and will be a under a battery leasing agreement (BaaS) with Aalborg Forsyning in Denmark. The location of the project is at Nordjyllandsværket power plant (one of three central coal fired facilities in Denmark today) as a commercial demonstration unit. Further, the project is part of a program with Nordjyllandsværket and Aalborg Varme to test and introduce new clean energy solutions and phase out coal. The thermal battery will provide heat to the local district heating system under a leasing contract where the energy input will be electricity from the grid.
The manufacturing process of the Heatcube has started and the specific unit will be configured with 18 MWh of storage capacity and 4 MW discharge load (compared to the standard design of 20 MWh/5 MW). The system will be delivered in 20-feet containers onsite, ready for integration. Notably, the modular design enables easy scale up on site by adding additional modules. Aalborg Varme sees great perspectives in the Heatcube, but first want to verify that it works with district heating. The Danish government has set a clear energy policy and a clear ambition to phase out coal from the power supply by 2030 and to phase out coal at Nordjyllandsværket in 2028.
Linkfire is the global market leader in smart links for music streaming companies with a 70% market share. For example, you click on Justin Bieber’s song you got from a friend on Snapchat, you get into a link that shows you where you can download the music from, the next concert, or where to buy tickers. That is Linkfire. They link music on social networks to music streaming companies.
Strong Q3 performance
Linkfire delivered Q3 very solid numbers. Revenues grew 42%, driven mainly by commission revenue that increased by 115%. The commission revenue strong growth was caused by a doubling of RPM (Revenue per thousand of customer connections). In the summary, robust quarter, another reconfirmation of the strong investment thesis.
Strong growth will continue
Strong growth is guided to continue
Snapchat and Twitch are signing licenses with music providers. Both are partners of Linkfire. As the licensed catalog rolls out, an uptake in consumer connections and revenue are expected.
Linkfire is talking to several additional partners. The partnership pipeline is maturing and Linkfire are indicating that they will announce more partnerships in the near future.
Both big and a bit smaller than big. There should be a lot of newsflow in the following quarters. This will drive revenues further.
RPM doubled vs. the last year Q3. The growth in RPM is expected to continue in the future, as the current number is still very small relative to RPM achieved in the best markets for Linkfire.
Linkfire is improving its technology to see higher conversion – which drives RPM higher.
Aquisition of SmartURL
SmartURL was the smart link pioneer that Linkfire overtook by its technological superiority and took over a few weeks ago.
In recent months, we have identified a wider range of M&A opportunities than previously anticipated. Both within areas of traffic growth but also market po[1]sitioning and complimentary entertainment verticals. Areas of particular inter[1]est for growth opportunities are podcasts and audiobooks, which not only is a strong fit for our product and technology but also an area of entertainment that is maturing very fast. Spoken Word’s share of audio listening has increased by 40% over the last seven years; 8% this year alone according to recent studies.
Linkfire is working on many partnership deals – Large as well as smaller
Linkfire is also talking to industry players aiming at consolidating the industry further
Podcasts and Audiobooks are next
LInkfire had a 70% market share in smart music links even prior to the smartURL acquisition.
The goal for the coming quarters is to replicate this in the next areas. In the IPO materials, Linkfire indicated they will want to enter Podcasts, Audiobooks, Movies and Games.
On the call, Linkfire management indicated that Podcasts and Audiobooks should be next on the agenda.
Linkfire has active dialogues with partners in Podcasts and Audiobooks area. Announcements on those should be made already next year.
Improved communications with investors
Linkfire started to communicate actively with its investors. The company set up FB, Twitter, and Linkedin pages where it shares news regularly.
Linkfire hired a PR team, and its investor relations representative should be coming along in a month’s time.
All the above shows that the management wants to communicate and does care about its investors.
Strong newsflow
The management indicated that there is very strong newsflow coming based on solid partner development
There will be plenty of newsflow related to new partnerships, M&A activities, both in the music area as well as in the new areas, such as Audiobooks and Podcasts.
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
We have been long AAC Clyde Space for a few months now. Today, Pareto Securities initiated coverage on the name. The 24 page report is quite bullish with price target of 10 SEK, a significant upside from today price of 2.8 SEK
Pareto Research Front Page Summary
(bold emphasis added):
Space coming to Earth
We initiate coverage of AAC Clyde Space, the small satellite spacecraft and service provider, with a Buy recommendation and 12-month target price of SEK 10 per share, supported by unjustifiably low EV/salesratios andour DCF valuation of SEK 20 per share. The emerging space market offers impressive growth opportunities and AAC Clyde Space is in pole position in the nanosatellite market. The urgent need for Earth monitoring to observe climate change and improve weather forecasts, using Space Data as a Service (SDaaS) from nanosatellites, is a powerful market driver. We expect the company to reach SEK 538m in sales in 2024 and positive operating cash flow in 2022.
Race in space SpaceX, deploying the broadband satellite network Starlink, will be a major driver of growth in the new emerging space market and fuel growth for AAC Clyde Space and other space companies. With a strong foothold in the nanosatellite market, with deliveries to proximately one third of the installed base of 1,000 satellites, we expect AAC Clyde Space to show a sales CAGR of nearly 50% in our forecast period of 2020 to 2025.
Equity rocketship The combination of being a not so well-known microcap stock, strong sales growth backed by a large order backlog and prospects for positive operating cashflow in 2022 all point to a strong investment case for AAC Clyde Space. From a sentiment point of view, the space sector is set to attract increasing interest in the coming years, with the IPO of SpaceX or Starlink as a main event. Our target price of SEK 10 per share, upside potential of 3x from the current level,should be ignited by sales growth in coming quarters and the de-risking of our 2022-2023 estimates.
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
Our family office was invited to participate on the call with Quantafuel (QFUEL) management on Friday 12/11/2021. The family office that invited us owns above 1% of QFUEL. Our family office has a material position in QFUEL too. There was no information that was not mentioned before, but several useful clarifications. I summarize below the main takeaways :
SKIVE
QFUEL already has in Skive or has confirmed deliveries of parts for all four lines modifications. There should be no delay with modifications on all lines.
The plant modifications have already started
Plant modifications are on schedule and should be completed in two-three weeks so that “cold plant testing” could begin in early December
guidance for CAPEX was reconfirmed. The mgmt indicated that they are “very comfortable” on the CAPEX – they see an opportunity to get below the guided CAPEX
Proof of concept – it is a self-imposed hurdle by QFUEL mgmt. They originally imposed three hurdles:
(i) run one line at the full capacity,
(ii) run two lines in parallel, and
(iii) run one line for a defined number of days and generate product at required specifications.
The first two hurdles were already achieved, the third is guided to be reached around the year-end.
After QFUEL achieves the Proof of Concept on one line, they will aim to reach continuous production. They are guiding that should be achieved in 1Q22.
All four lines are guided to be running at continuous production in 2Q22
Kristiansund
operation of the 20k mechanical line is on track to start during December 2021.
the line should produce an annual EBITDA of 25 million NOK
It will be the first operating and cash-generating plant for QFUEL
FIDs for large plants
the first FID for a large plant should be with Vitol, sometimes at mid-year 2022. At the moment, QFUEL is working with Vitol on a feasibility study and obtaining plant permits. So the Vitol project is already progressing
BASF FID probably after Vitol FID
Large plant economics
100k ton plant should cost 100-150 mil USD. That is what was previously guided. QFUEL mgmt indicated they should get below the guided range
The plant should produce EBITDA of 50 mil USD annually
The payback for a plant should be 2-3 years at the EBITDA level. If you take taxes and financing into account, payback should be around 4 years.
CO2 Permits
many companies are generating revenue from selling CO2 permits.
QFUEL is planning to look into this opportunity – they are finding ways whether there is a possibility to obtain CO2 permits from Denmark’s government for the Skive plant.
OUR TAKE
It was positive to see management confidence in reaching the proof of concept around the New Year.
Share price impact: If you look at past price performance, when the market expected proof of concept, the share price jumped above 70 NOK. The share price could easily beat this when proof of concept is achieved. That is 150% upside. If the proof of concept is again delayed, you could seek QFUEL declining to low 20s NOK. That is 20% downside. 150% upside vs 20% downside seems like a good risk reward.
The company is very active in preparing new plant projects. Once the proof of concept is achieved, there should be a lot of traction – there will be four large plants under construction at the same time. There should be a lot of positive newsflow.
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
I looked through the research published today. The main points can be summarized as follows:
Skive reconstruction is on schedule, no delay and no change of costs guidance
Proof of concept expected around the year end – just a few weeks away
All four Skive four lines in full operation in 2Q22
Skive should be cash flow positive in 2022
Kristiansund mechanical recycling plant with capacity 20kt should start operations in December 2021 – should generate positive cashflow in 2022
QFUEL as whole cash flow positive in 22
Upon proof of concept QFUEL expects to progress on the big plants with its strategic partners.
First mega plant most likely with Vitol in Amsterdam
I below select parts from different research reports that I found interesting
Fearnley
Going forward, QFUEL is targeting a positive cash flow from operations by end 2022, driven by Skive capacity target of 12kt to a total of 20kt plastic waste processed next year. QFUEL guides Skive to deliver NOK 80m in EBITDA p.a. at full capacity, and the mechanical line at Kristiansund NOK 25m p.a. at new target capacity of 20kt.
Pareto
Upon proof of concept, Quantafuel states that it is ready to roll out the announced projects. Initially, this refers to the project in Amsterdam together with Vitol and VTTI, in UK and in Esbjerg. Quantafuel experiences increasing payments for taking plastic waste and sales prices significantly above its budgets. In addition, it comments that product quality continues to be in line with BASF offtake agreement. However, modifications will be made to new plants to yield the future BASF target production specifications as Skive was built to maximize the output initial partner Vitol wanted (low carbon diesel vs naphtha for BASF).
In sum, positive that the company seem confident in reaching proof-of-concept in only weeks
ABG Sundal Collier
The product produced at Skive is in line with the current offtake agreement with BASF, but it also states that the future BASF naptha spec is stricter and will require further process development (not on Skive but future plants). Remaining capex is NOK ~145m vs NOK 70m in Q2,explained by the announced investment in the Aalborg sorting facility and additional mechanical sorting capacity in Kristiansund. It has NOK 379m in cash at quarter end. It provides some more detailed financial guidance, incl stating to have positive cash flow from operations as it exits ’22. This means it could have NOK ~0.2bn in cash by YE’22 excluding additional growth capex. It has added the UK/Sunderland plant to its roll-out plan and states it expects to start construction on the sorting part of Esbjerg mid’22 subject to financing and with partner discussions ongoing.
If the company manages to deliver proof of concept, there is a lot of news-flow on the big plans in the next months. I believe the share price could easily regain this year highs within a few quarters. Very attractive risk reward
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice.
Fit Investment Ideas 